Waldencast sees FY25 net revenue ‘broadly in line’ with 2024

The company said,”Our updated full-year outlook reflects Obagi Medical’s performance in line with expectations and incorporates a moderated expectation for Milk Makeup due to softer consumption and continued investment to position the brand for future success. As a result, we now expect net revenue to be broadly in line with 2024 and Adjusted EBITDA Margin in the high single digits. We remain confident in our ability to drive sustainable growth on both brands, as we continue to capitalize on and invest in strong innovation, digital capabilities, new distribution channels, and process efficiencies. Given our high gross margin business model and limited reliance on Asian sourcing, we expect a limited increase in cost of goods with any necessary price adjustments to offset the changing tariff environment.”